OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
300920$45.4959

Zhejiang Runyang New Material Technology Co Ltd

Commodity ChemicalsVerified

Zhejiang Runyang New Material Technology Co Ltd has a market capitalization of 4.55 billion CNY and a price-to-earnings ratio of 168.69, indicating a high valuation relative to earnings. The company's price-to-book ratio is 3.84, suggesting that the market values the company at a premium to its book value. The enterprise value to EBITDA ratio is 257.56, which is significantly higher than typical industry benchmarks, indicating a high valuation relative to operating performance. The company's profitability metrics are modest. Return on equity is 2.28%, and return on assets is 1.69%, both below the industry median for commodity chemicals. The net profit margin is 6.39% (26.97 million CNY net income on 421.91 million CNY revenue), which is also below the industry average. The company's operating margin is 4.47%, further underscoring the pressure on profitability in a competitive commodity chemicals market. Zhejiang Runyang's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's exposure to the Chinese domestic market is high, and it does not report revenue by region or product line. This lack of diversification increases vulnerability to regional economic shifts and regulatory changes. The company's growth trajectory is mixed. Revenue in the latest period was 421.91 million CNY, but there is no disclosed prior period for comparison. Analysts expect earnings per share to increase from 0.27 CNY to 0.59 CNY, a 118.5% increase, but this is based on a single "buy" recommendation with no strong buy or hold ratings. The company's capital expenditures were -110.99 million CNY, indicating a significant outflow, and free cash flow was negative at -59.28 million CNY, suggesting operational cash flow is insufficient to cover capital spending. The company faces moderate liquidity risk, with a current ratio of 1.49 and a debt-to-equity ratio of 0.26. However, the risk assessment notes that net cash is negative after subtracting total debt, indicating a potential liquidity constraint. The dilution risk is low, with no near-term pressure from share issuance or convertible debt. The company's capital structure is stable, with long-term debt at 306.71 million CNY and total equity at 1.18 billion CNY. Recent events include a single analyst "buy" recommendation and no strong buy or sell ratings. The company's earnings per share have not met analyst expectations, with the last actual EPS at 0.27 CNY versus a mean estimate of 0.59 CNY. No recent filings or transcripts have been disclosed that would indicate significant operational or strategic changes.

30-day price · 300920+5.09 (+13.3%)
Low$38.06High$48.37Close$43.47As of21 May, 00:00 UTC
Profile
CompanyZhejiang Runyang New Material Technology Co Ltd
Ticker300920.SZ
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Zhejiang Runyang New Material Technology Co Ltd is a Chinese chemical company that produces and sells commodity chemicals, primarily serving industrial and manufacturing sectors.

Classification. The company is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry with a confidence level of 0.92.

Zhejiang Runyang New Material Technology Co Ltd has a market capitalization of 4.55 billion CNY and a price-to-earnings ratio of 168.69, indicating a high valuation relative to earnings. The company's price-to-book ratio is 3.84, suggesting that the market values the company at a premium to its book value. The enterprise value to EBITDA ratio is 257.56, which is significantly higher than typical industry benchmarks, indicating a high valuation relative to operating performance. The company's profitability metrics are modest. Return on equity is 2.28%, and return on assets is 1.69%, both below the industry median for commodity chemicals. The net profit margin is 6.39% (26.97 million CNY net income on 421.91 million CNY revenue), which is also below the industry average. The company's operating margin is 4.47%, further underscoring the pressure on profitability in a competitive commodity chemicals market. Zhejiang Runyang's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's exposure to the Chinese domestic market is high, and it does not report revenue by region or product line. This lack of diversification increases vulnerability to regional economic shifts and regulatory changes. The company's growth trajectory is mixed. Revenue in the latest period was 421.91 million CNY, but there is no disclosed prior period for comparison. Analysts expect earnings per share to increase from 0.27 CNY to 0.59 CNY, a 118.5% increase, but this is based on a single "buy" recommendation with no strong buy or hold ratings. The company's capital expenditures were -110.99 million CNY, indicating a significant outflow, and free cash flow was negative at -59.28 million CNY, suggesting operational cash flow is insufficient to cover capital spending. The company faces moderate liquidity risk, with a current ratio of 1.49 and a debt-to-equity ratio of 0.26. However, the risk assessment notes that net cash is negative after subtracting total debt, indicating a potential liquidity constraint. The dilution risk is low, with no near-term pressure from share issuance or convertible debt. The company's capital structure is stable, with long-term debt at 306.71 million CNY and total equity at 1.18 billion CNY. Recent events include a single analyst "buy" recommendation and no strong buy or sell ratings. The company's earnings per share have not met analyst expectations, with the last actual EPS at 0.27 CNY versus a mean estimate of 0.59 CNY. No recent filings or transcripts have been disclosed that would indicate significant operational or strategic changes.
Key takeaways
  • The company is valued at a high multiple of earnings and book value, suggesting market optimism despite modest profitability.
  • Profitability metrics are below industry medians, indicating operational inefficiencies or pricing pressures.
  • Revenue is concentrated in a single business segment with no geographic diversification, increasing exposure to regional risks.
  • Analysts expect strong earnings growth, but this is based on a single "buy" recommendation with no strong buy or hold ratings.
  • The company has negative free cash flow and a high capital expenditure outflow, indicating a capital-intensive business model.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$421.9M
Gross profit$92.1M
Operating income$18.9M
Net income$27.0M
R&D
SG&A
D&A
SBC
Operating cash flow$41.5M
CapEx-$111.0M
Free cash flow-$59.3M
Total assets$1.60B
Total liabilities$413.0M
Total equity$1.18B
Cash & equivalents
Long-term debt$306.7M
Valuation
Market price$45.49
Market cap$4.55B
Enterprise value$4.86B
P/E168.7
Reported non-GAAP P/E
EV/Revenue11.5
EV/Op income257.6
EV/OCF117.1
P/B3.8
P/Tangible book3.8
Tangible book$1.18B
Net cash-$306.7M
Current ratio1.5
Debt/Equity0.3
ROA1.7%
ROE2.3%
Cash conversion1.5%
CapEx/Revenue-26.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
Metric300920Activity
Op margin4.5%0.4% medp25 -8.0% · p75 16.0%above median
Net margin6.4%2.3% medp25 -11.6% · p75 11.8%above median
Gross margin21.8%20.8% medp25 14.9% · p75 24.0%above median
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-26.3%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity26.0%59.0% medp25 54.9% · p75 72.9%bottom quartile
Observations
IR observations
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.59 CNY
Last actual EPS0.27 CNY
Mean revenue estimate678,000,000 CNY
Last actual revenue421,909,440 CNY
Source: analysis-pipeline (hybrid)Generated: 2026-05-21 05:38 UTCJob: 6b35ee46